VKH
SLNO

Virtu KCG Holdings’s Soleno Therapeutics SLNO Stock Holding History

Virtu KCG Holdings’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-151
Closed -$10K – 3764
2016
Q3 		$10K Buy
151
+15
+11% +$1.14K ﹤0.01% 2976
2016
Q2 		$12K Buy
+136
New +$12.4K ﹤0.01% 2836
2016
Q1 		– Sell
-392
Closed -$54K – 3569
2015
Q4 		$54K Buy
392
+233
+147% +$34.1K ﹤0.01% 3141
2015
Q3 		$25K Sell
159
-26
-14% -$4.71K ﹤0.01% 3124
2015
Q2 		$39K Buy
+185
New +$71.1K ﹤0.01% 3107

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.29B AUM 4.86% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 374.31% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Virtu KCG Holdings's SLNO Position: Q4 2016 in Review

Virtu KCG Holdings sold out of Soleno Therapeutics (SLNO) in Q4 2016, closing a stake of 151 shares — an estimated $10K sold.

Virtu KCG Holdings first reported a position in SLNO in Q2 2015 and held it in 5 quarters. The position peaked at $54K in Q4 2015. 12 funds tracked by Wall St. Rank hold SLNO as of Q4 2016.

  • Virtu KCG Holdings reported no remaining Soleno Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Virtu KCG Holdings sold 151 Soleno Therapeutics shares in Q4 2016, an estimated $10K.
  • Virtu KCG Holdings first reported a position in Soleno Therapeutics in Q2 2015 and held it in 5 quarters.
  • Virtu KCG Holdings's Soleno Therapeutics position peaked at $54K in Q4 2015.
  • 12 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2016.

Based on Virtu KCG Holdings's 13F filing for Q4 2016, filed 10 Feb 2017.